1306721-26-5

Basic information

• Product Name: 4-[4-(acryloyl-methyl-amino)-benzenesulfonyl]-piperazine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-[4-(acryloyl-methyl-amino)-benzenesulfonyl]-piperazine-1-carboxylic acid tert-butyl ester
• CAS NO: 1306721-26-5
• Molecular Weight: 409.506
• Mol File: 1306721-26-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[4-(acryloyl-methyl-amino)-benzenesulfonyl]-piperazine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(acryloyl-methyl-amino)-benzenesulfonyl]-piperazine-1-carboxylic acid tert-butyl ester(1306721-26-5)
• EPA Substance Registry System: 4-[4-(acryloyl-methyl-amino)-benzenesulfonyl]-piperazine-1-carboxylic acid tert-butyl ester(1306721-26-5)

Safety Data

• Hazardous Substances Data: 1306721-26-5(Hazardous Substances Data)

Upstream product

• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 173951-84-3 4-((4-aminophenyl)sulfonyl)-1-(tert-butyloxycarbonyl)piperazine 
• 173951-83-2 N-((4-nitrophenyl)sulfonyl)-1-(tert-butyloxycarbonyl)piperazine 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 
• 1306720-00-2 4-(4-acryloylaminobenzenesulfonyl)piperazine-1-carboxylic acid tert-butyl ester 
• 74-88-4 methyl iodide 

Relevant articles and documents

TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.